WallStSmart

Agilent Technologies Inc (A)vsVeracyte Inc (VCYT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Agilent Technologies Inc generates 1266% more annual revenue ($7.07B vs $517.14M). A leads profitability with a 18.3% profit margin vs 12.8%. A trades at a lower P/E of 24.9x. A earns a higher WallStSmart Score of 61/100 (C+).

A

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 7.3Quality: 5.3
Piotroski: 3/9Altman Z: 1.99

VCYT

Buy

59

out of 100

Grade: C

Growth: 8.0Profit: 5.5Value: 7.0Quality: 9.0
Piotroski: 4/9Altman Z: 6.05
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASignificantly Overvalued (-318.5%)

Margin of Safety

-318.5%

Fair Value

$30.80

Current Price

$112.98

$82.18 premium

UndervaluedFair: $30.80Overvalued
VCYTUndervalued (+3.9%)

Margin of Safety

+3.9%

Fair Value

$37.44

Current Price

$32.79

$4.65 discount

UndervaluedFair: $37.44Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

A2 strengths · Avg: 8.5/10
Return on EquityProfitability
20.0%9/10

Every $100 of equity generates 20 in profit

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

VCYT4 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
6.0510/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
18.5%8/10

18.5% revenue growth

Areas to Watch

A3 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-3.6%2/10

Earnings declined 3.6%

VCYT2 concerns · Avg: 2.5/10
Return on EquityProfitability
5.3%3/10

ROE of 5.3% — below average capital efficiency

P/E RatioValuation
41.2x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : A

The strongest argument for A centers on Return on Equity, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 22.9%. PEG of 1.19 suggests the stock is reasonably priced for its growth.

Bull Case : VCYT

The strongest argument for VCYT centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 18.5% demonstrates continued momentum.

Bear Case : A

The primary concerns for A are Altman Z-Score, Piotroski F-Score, EPS Growth.

Bear Case : VCYT

The primary concerns for VCYT are Return on Equity, P/E Ratio. A P/E of 41.2x leaves little room for execution misses.

Key Dynamics to Monitor

A profiles as a mature stock while VCYT is a growth play — different risk/reward profiles.

VCYT carries more volatility with a beta of 1.96 — expect wider price swings.

VCYT is growing revenue faster at 18.5% — sustainability is the question.

A generates stronger free cash flow (175M), providing more financial flexibility.

Bottom Line

A scores higher overall (61/100 vs 59/100), backed by strong 18.3% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agilent Technologies Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

Veracyte Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.

Want to dig deeper into these stocks?